Overexpression of C/EBPβ-LIP, a naturally occurring, dominant- negative transcription factor, in human breast cancer

Cynthia A. Zahnow, Pamela Younes, Rodolfo Laucirica, Jeffrey M. Rosen

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

Background: When cells fail to maintain a balance between proliferation, terminal differentiation, and programmed cell death, cancer often results. The CCAAT/enhancer-binding protein (C/EBP) family of transcription factors regulates many genes involved in the processes of proliferation and terminal differentiation. The messenger RNA for C/EBPβ is translated into two major isoforms, LAP (liver-enriched activating protein) and LIP (liver-enriched inhibitory protein). LIP levels appear to be elevated in mouse mammary tumors but not in hyperplastic mammary tissues. We tested whether LIP expression is elevated in human breast cancer and whether elevated expression is associated with biologic predictors of the aggressiveness of the disease. Methods: Homogenates of infiltrating ductal carcinoma specimens from 39 women were analyzed for C/EBPβ protein content by western blot analysis, and the ratio of LAP to LIP in specimens containing high levels of LIP (i.e., levels approximately 15 times higher than those in tumor specimens that express little or no LIP) was also determined. Nonparametric statistical analyses were performed. Results: LIP was present at high levels in nine of 39 specimens of infiltrating ductal carcinoma. Eight of the nine specimens of infiltrating ductal carcinoma that contained high levels of LIP were negative for estrogen receptor and progesterone receptor (ER-/PR-); all nine tumors were aneuploid and poorly differentiated, and eight of nine were highly proliferative. Of the tumors that contained LIP at low or nondetectable levels, six of 30 were ER-/PR-, 17 of 29 were aneuploid, eight of 27 were highly proliferative, and 11 of 30 were poorly differentiated. Implication: LIP expression should be evaluated further as a prognostic marker for patients with breast cancer.

Original languageEnglish (US)
Pages (from-to)1887-1891
Number of pages5
JournalJournal of the National Cancer Institute
Volume89
Issue number24
StatePublished - Dec 17 1997

Fingerprint

CCAAT-Enhancer-Binding Proteins
Transcription Factors
Breast Neoplasms
Liver
Proteins
Ductal Carcinoma
Aneuploidy
Progesterone Receptors
Estrogen Receptors
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Overexpression of C/EBPβ-LIP, a naturally occurring, dominant- negative transcription factor, in human breast cancer. / Zahnow, Cynthia A.; Younes, Pamela; Laucirica, Rodolfo; Rosen, Jeffrey M.

In: Journal of the National Cancer Institute, Vol. 89, No. 24, 17.12.1997, p. 1887-1891.

Research output: Contribution to journalArticle

@article{5fce7e256ae7427280af4fbfbb65110c,
title = "Overexpression of C/EBPβ-LIP, a naturally occurring, dominant- negative transcription factor, in human breast cancer",
abstract = "Background: When cells fail to maintain a balance between proliferation, terminal differentiation, and programmed cell death, cancer often results. The CCAAT/enhancer-binding protein (C/EBP) family of transcription factors regulates many genes involved in the processes of proliferation and terminal differentiation. The messenger RNA for C/EBPβ is translated into two major isoforms, LAP (liver-enriched activating protein) and LIP (liver-enriched inhibitory protein). LIP levels appear to be elevated in mouse mammary tumors but not in hyperplastic mammary tissues. We tested whether LIP expression is elevated in human breast cancer and whether elevated expression is associated with biologic predictors of the aggressiveness of the disease. Methods: Homogenates of infiltrating ductal carcinoma specimens from 39 women were analyzed for C/EBPβ protein content by western blot analysis, and the ratio of LAP to LIP in specimens containing high levels of LIP (i.e., levels approximately 15 times higher than those in tumor specimens that express little or no LIP) was also determined. Nonparametric statistical analyses were performed. Results: LIP was present at high levels in nine of 39 specimens of infiltrating ductal carcinoma. Eight of the nine specimens of infiltrating ductal carcinoma that contained high levels of LIP were negative for estrogen receptor and progesterone receptor (ER-/PR-); all nine tumors were aneuploid and poorly differentiated, and eight of nine were highly proliferative. Of the tumors that contained LIP at low or nondetectable levels, six of 30 were ER-/PR-, 17 of 29 were aneuploid, eight of 27 were highly proliferative, and 11 of 30 were poorly differentiated. Implication: LIP expression should be evaluated further as a prognostic marker for patients with breast cancer.",
author = "Zahnow, {Cynthia A.} and Pamela Younes and Rodolfo Laucirica and Rosen, {Jeffrey M.}",
year = "1997",
month = "12",
day = "17",
language = "English (US)",
volume = "89",
pages = "1887--1891",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "24",

}

TY - JOUR

T1 - Overexpression of C/EBPβ-LIP, a naturally occurring, dominant- negative transcription factor, in human breast cancer

AU - Zahnow, Cynthia A.

AU - Younes, Pamela

AU - Laucirica, Rodolfo

AU - Rosen, Jeffrey M.

PY - 1997/12/17

Y1 - 1997/12/17

N2 - Background: When cells fail to maintain a balance between proliferation, terminal differentiation, and programmed cell death, cancer often results. The CCAAT/enhancer-binding protein (C/EBP) family of transcription factors regulates many genes involved in the processes of proliferation and terminal differentiation. The messenger RNA for C/EBPβ is translated into two major isoforms, LAP (liver-enriched activating protein) and LIP (liver-enriched inhibitory protein). LIP levels appear to be elevated in mouse mammary tumors but not in hyperplastic mammary tissues. We tested whether LIP expression is elevated in human breast cancer and whether elevated expression is associated with biologic predictors of the aggressiveness of the disease. Methods: Homogenates of infiltrating ductal carcinoma specimens from 39 women were analyzed for C/EBPβ protein content by western blot analysis, and the ratio of LAP to LIP in specimens containing high levels of LIP (i.e., levels approximately 15 times higher than those in tumor specimens that express little or no LIP) was also determined. Nonparametric statistical analyses were performed. Results: LIP was present at high levels in nine of 39 specimens of infiltrating ductal carcinoma. Eight of the nine specimens of infiltrating ductal carcinoma that contained high levels of LIP were negative for estrogen receptor and progesterone receptor (ER-/PR-); all nine tumors were aneuploid and poorly differentiated, and eight of nine were highly proliferative. Of the tumors that contained LIP at low or nondetectable levels, six of 30 were ER-/PR-, 17 of 29 were aneuploid, eight of 27 were highly proliferative, and 11 of 30 were poorly differentiated. Implication: LIP expression should be evaluated further as a prognostic marker for patients with breast cancer.

AB - Background: When cells fail to maintain a balance between proliferation, terminal differentiation, and programmed cell death, cancer often results. The CCAAT/enhancer-binding protein (C/EBP) family of transcription factors regulates many genes involved in the processes of proliferation and terminal differentiation. The messenger RNA for C/EBPβ is translated into two major isoforms, LAP (liver-enriched activating protein) and LIP (liver-enriched inhibitory protein). LIP levels appear to be elevated in mouse mammary tumors but not in hyperplastic mammary tissues. We tested whether LIP expression is elevated in human breast cancer and whether elevated expression is associated with biologic predictors of the aggressiveness of the disease. Methods: Homogenates of infiltrating ductal carcinoma specimens from 39 women were analyzed for C/EBPβ protein content by western blot analysis, and the ratio of LAP to LIP in specimens containing high levels of LIP (i.e., levels approximately 15 times higher than those in tumor specimens that express little or no LIP) was also determined. Nonparametric statistical analyses were performed. Results: LIP was present at high levels in nine of 39 specimens of infiltrating ductal carcinoma. Eight of the nine specimens of infiltrating ductal carcinoma that contained high levels of LIP were negative for estrogen receptor and progesterone receptor (ER-/PR-); all nine tumors were aneuploid and poorly differentiated, and eight of nine were highly proliferative. Of the tumors that contained LIP at low or nondetectable levels, six of 30 were ER-/PR-, 17 of 29 were aneuploid, eight of 27 were highly proliferative, and 11 of 30 were poorly differentiated. Implication: LIP expression should be evaluated further as a prognostic marker for patients with breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0031283125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031283125&partnerID=8YFLogxK

M3 - Article

C2 - 9414177

AN - SCOPUS:0031283125

VL - 89

SP - 1887

EP - 1891

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 24

ER -